Nov 28, 2023 / 02:10PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Okay. Excellent. Well, thank you guys for being here. Pleasure to have Biogen management join us. We're only going to talk about the 10,000 patients by end of March and no other topic. But in all seriousness, thank you, Priya, for being here. I'll turn it over to you to kick things off.
Priya Singhal - Biogen Inc. - Executive VP & Head of Development
Sure. So delighted to be here. I think we believe we've had a really good year and met all the business priorities that we set out -- Chris set out at the outset of the year. So it was about the launches, the approvals, the R&D prioritization, recruiting a new head of research, and really focusing attention on the new wave of products that we believe we have the ability and capability to bring to patients with high unmet need. And I think that on all of these priorities, we feel we've made significant progress and we are entering 2024 really with a lot of promise and a lot of things to look
Biogen Inc at Evercore ISI HealthCONx Conference Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers